NantHealth
Healthcare technology company providing software, precision-medicine, and clinical decision-support solutions.
Last updated August 24, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
NantHealth, Inc. is a United States healthcare technology company focused on software and data services for clinical care, precision medicine, and healthcare administration. The company was founded by physician, entrepreneur, and investor Patrick Soon-Shiong and operates within the broader NantWorks portfolio. Its business has included technology for insurers, providers, patients, and clinical researchers, with an emphasis on bringing medical, genomic, and operational information together in healthcare workflows. The company’s best-known offerings include NaviNet, a healthcare network and administrative platform used by health plans and providers, and clinical decision-support systems designed to help clinicians interpret patient information and make treatment decisions. NantHealth has also promoted genomic and precision-oncology services, including GPS Cancer, a platform associated with genomic analysis and individualized cancer-treatment guidance. These activities place the company at the intersection of health information technology, oncology, genomic medicine, and connected care rather than in the traditional hospital-operator category. NantHealth received substantial attention before and around its public-market debut. Its profile was heightened by a September 2014 Forbes cover story, which discussed the company and estimated its market capitalization at approximately $1.6 billion at that time. In December 2014, NantHealth was featured on the CBS program 60 Minutes in a segment presented by Sanjay Gupta. Early investors and strategic participants reported in reference material included Allscripts, BlackBerry, the Kuwait Investment Authority, Celgene, and Verizon. The company has also faced the financial and operating pressures common to smaller public healthcare-technology businesses. In January 2019, Nasdaq notified NantHealth that its common stock had failed to maintain the exchange’s minimum closing-bid requirement of $1.00 for 30 consecutive business days. NantHealth later carried out a one-for-fifteen reverse stock split in December 2022. NantWorks remained the controlling shareholder by voting power at the end of 2021, with the reference material reporting a 62 percent voting interest. NantHealth’s public description is therefore best understood as a healthcare software and precision-medicine business, not as a hospital system. Its offerings have historically addressed clinical information exchange, payer-provider connectivity, genomic interpretation, treatment decision support, and related digital-care infrastructure. Publicly available reference material does not establish a complete current product catalog, detailed present-day geographic footprint, or a comprehensive list of current executives; those fields are consequently limited to information that can be supported.
History
NantHealth was established by Patrick Soon-Shiong as part of the broader NantWorks group, whose businesses have pursued applications of biotechnology, medicine, and digital technology. The company developed a healthcare-technology identity around the use of integrated data to support medical decisions and improve coordination among healthcare participants. Rather than operating hospitals, NantHealth built software and services for organizations involved in care delivery and payment. Its activities have included payer-provider connectivity, clinical information management, decision-support tools, and precision medicine. NaviNet became an important part of the company's healthcare-administration offering, providing a network and software environment associated with communication and transactions between health plans and providers. NantHealth also developed or promoted systems intended to help clinicians use patient and genomic information in treatment planning. GPS Cancer represented the company's precision-oncology direction, linking genomic analysis with information intended to inform individualized cancer-care decisions. The company attracted considerable attention in the mid-2010s. A Forbes cover story in September 2014 presented NantHealth as a prominent healthcare-technology venture and gave an estimated market capitalization of about $1.6 billion. In December of the same year, a 60 Minutes feature presented by Sanjay Gupta further raised its public profile. The company also received backing or strategic investment from several notable organizations, including Allscripts, BlackBerry, the Kuwait Investment Authority, Celgene, and Verizon, according to the referenced account. NantHealth became a publicly traded company, giving it access to public capital markets but also exposing it to exchange-listing requirements and shareholder scrutiny. In January 2019, Nasdaq issued a deficiency notice because the company's shares had not maintained a closing bid of at least $1.00 for thirty consecutive business days. The notice did not itself establish that the company had ceased operating, but it illustrated the financial pressure facing the business as a smaller listed healthcare-technology company. In December 2022, NantHealth carried out a one-for-fifteen reverse stock split, consolidating shares and addressing the company's capital-structure and trading-price circumstances. Commercial expansion of GPS Cancer continued to be pursued through partnerships. In August 2017, NantHealth signed a distribution agreement with Asia Genomics. The agreement indicated an effort to make the precision-oncology offering available through an external regional channel, although the available reference material does not provide detailed performance results or the agreement's subsequent commercial outcome. At the end of 2021, NantWorks was reported to control 62 percent of NantHealth's voting shares. This voting position connected NantHealth's governance and strategic direction closely to the NantWorks group. Public reference material does not provide enough information to construct a reliable account of all later products, operating results, leadership changes, or geographic markets. The company is therefore documented here as a healthcare software and precision-medicine brand whose principal historical themes are clinical data integration, payer-provider connectivity, genomic oncology, public-market financing, and control by NantWorks.
- 2022
One-for-fifteen reverse stock split
[1]NantHealth completed a reverse stock split consolidating fifteen existing shares into one share.
- 2021
NantWorks reported as controlling shareholder
[1]NantWorks was reported to control 62 percent of NantHealth's voting shares at the end of the year.
- 2019
Nasdaq listing-compliance warning
[1]Nasdaq warned NantHealth that its stock had not maintained the required minimum closing bid price for thirty consecutive business days.
- 2017
GPS Cancer distribution agreement
[1]NantHealth signed a distribution agreement with Asia Genomics for GPS Cancer.
- 2014
Forbes cover feature
[1]NantHealth was featured on the cover of Forbes, which reported an estimated market capitalization of approximately $1.6 billion at the time.
- 2014
60 Minutes feature
[1]The company appeared on 60 Minutes in a segment presented by Sanjay Gupta, raising its public profile in healthcare technology and precision medicine.
Products and positioning
A healthcare information-technology and precision-medicine provider that connects clinical, genomic, and administrative data to support payers, providers, and treatment decisions.
Healthcare administrative and payer-provider connectivity software
NaviNet
NaviNet is a healthcare software and network offering associated with communication and administrative workflows between health plans and providers. It is described as serving insurance companies and supporting the exchange of information needed in payer-provider interactions. The available reference material does not provide a complete current feature list, pricing model, or implementation footprint.
Precision oncology and genomic decision support
GPS Cancer
GPS Cancer is NantHealth's precision-oncology offering, associated with genomic analysis and individualized cancer-treatment guidance. The platform reflects the company's effort to connect molecular information with clinical decision-making. In 2017, NantHealth signed a distribution agreement with Asia Genomics, indicating an attempt to extend the offering through a regional commercial partner.
Clinical software
Clinical decision-support systems
NantHealth has provided decision-support systems intended for healthcare organizations and clinicians. These systems are positioned around the use of clinical, patient, and potentially genomic information to support care decisions. The reference material identifies the category but does not establish a definitive product list, current release status, or detailed technical specifications.
Marketing campaigns
- 2014Forbes visibility campaign
United States
NantHealth received major business-media exposure through a Forbes cover story that presented the company as a notable healthcare-technology venture.
Outcome. The feature increased public visibility, but the available material does not document measurable commercial results.
- 201460 Minutes feature
United States
A 60 Minutes segment presented by Sanjay Gupta introduced NantHealth's healthcare-technology ambitions to a broad television audience.
Outcome. The appearance raised awareness of the company; specific conversion or sales outcomes are not available in the reference material.
Brand decisions
2022
Reverse stock splitOtherBackground
NantHealth was a publicly traded company whose shares had previously faced minimum-bid-price pressure under Nasdaq listing rules.
Action taken
The company completed a one-for-fifteen reverse stock split in December.
Aftermath
The transaction reduced the number of outstanding shares and increased the quoted price per share on a split-adjusted basis. The reference material does not establish its longer-term listing or trading outcome.
2017
Regional distribution strategy for GPS CancerStrategyBackground
NantHealth sought to distribute its precision-oncology offering beyond its core United States market.
Action taken
The company signed a distribution agreement with Asia Genomics for GPS Cancer.
Aftermath
The agreement demonstrated an international channel strategy, but the available source does not report subsequent sales or clinical-adoption results.
Recent events
- 2022
NantHealth completes one-for-fifteen reverse stock split[1]
Other
NantHealth implemented a reverse stock split in December 2022, consolidating every fifteen shares into one share. The action followed the company's earlier history of public-market trading pressure.
- 2019
NantHealth receives Nasdaq minimum-bid-price deficiency notice[1]
Regulation
Nasdaq notified NantHealth that its common stock had remained below the exchange's minimum closing bid price of $1.00 for 30 consecutive business days, creating a compliance issue for the publicly traded company.
- 2017
NantHealth signs GPS Cancer distribution agreement with Asia Genomics[1]
M&A · Product launch
NantHealth entered a distribution agreement with Asia Genomics for GPS Cancer, expanding the potential distribution of its precision-oncology offering in Asian markets.
- 2014
NantHealth appears on 60 Minutes[1]
Campaign
NantHealth was featured on 60 Minutes in a segment presented by Sanjay Gupta, increasing public visibility for the company's healthcare-technology and precision-medicine ambitions.
- 2014
NantHealth featured on Forbes cover[1]
Other
A Forbes cover story highlighted NantHealth and estimated its market capitalization at approximately $1.6 billion at the time. The figure is historical and should not be interpreted as a current valuation.
Sources2 sources
Cite this profile: Cite the canonical profile. /brand-wiki/nanthealth · Editorial policy · How profiles are compiled